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The classic renin-angiotensin system (RAS) was initially described as a hormone system designed to mediate cardiovascular
and body water regulation. The discovery of a brain RAS composed of the necessary functional components (angiotensinogen,
peptidases, angiotensins, and speciﬁc receptor proteins) independent of the peripheral system signiﬁcantly expanded the possible
physiological and pharmacological functions of this system. This paper ﬁrst describes the enzymatic pathways resulting in
active angiotensin ligands and their interaction with AT1,A T 2, and mas receptor subtypes. Recent evidence points to important
contributions by brain angiotensin III (AngIII) and aminopeptidases A (APA) and N (APN) in sustaining hypertension. Next,
we discuss current approaches to the treatment of hypertension followed by novel strategies that focus on limiting the binding of
AngII and AngIII to the AT1 receptor subtype by inﬂuencing the activity of APA and APN. We conclude with thoughts concerning
future treatment approaches to controlling hypertension and hypotension.
1.Introduction
The ﬁrst physiological insight into blood pressure (BP) reg-
ulation was the isolation of kidney renin by Tigerstedt and
Bergman in 1897 [1]. This initial work led to a description
of renovascular hypertension in animals and humans by
Goldblatt and colleagues. [2]. In 1940, Braun-Menendez and
coworkers [3] isolated a vasoconstrictive substance from
renal venous blood taken from a Goldblatt hypertensive dog.
In this same year, Page and Helmer [4] isolated a “renin
activator” after injecting renin into an intact animal. This
renin activator was later identiﬁed as angiotensinogen. The
pressor substance was termed “angiotonin” (also referred
to as “hypertension”), and was eventually shown to be an
octapeptide [5–7]. It was agreed by Braun-Mendez and Page
in 1958 to name this octapeptide “angiotensin.” Since that
time extensive physiological, biochemical and behavioral
studies have established a prominent role for angiotensin in
blood pressure and body water/electrolyte balance.
This paper initially describes the presently identiﬁed
angiotensin ligands of the renin-angiotensin system (RAS)
and details the enzymes involved in their formation and
degradation. The two prominent angiotensin receptor sub-
types that bind these ligands (AT1 and AT2)h a v eb e e n
characterized, as have the roles of angiotensin II (AngII)
and angiotensin III (AngIII) in blood pressure regulation.
We next focus on current and novel approaches designed
to treat hypertension by manipulating aminopeptidases. We
conclude with some thoughts on future directions concern-
ing treatment strategies to control hypertension.
2. Formation of AngiotensinLigands
Angiotensin peptides are derived from the precursor protein
angiotensinogenthroughseveralenzymaticconversionpath-
ways(Figure1[8–10]).ThedecapeptideangiotensinI(AngI)
is formed by renin (EC 3.4.23.15) acting upon the amino
terminal of angiotensinogen [11]. AngI serves as a substrate2 International Journal of Hypertension
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Figure 1: The renin-angiotensin pathway including active ligands (bold), enzymes, receptors, and inhibitors involved in central angiotensin
mediated blood pressure. Abbreviations: ACE: angiotensin converting enzyme; APA: aminopeptidase A; APN: aminopeptidase N; ARBs:
angiotensin receptor blockers.
for angiotensin converting enzyme (ACE: EC 3.4.15.1), a
zinc metalloprotease that hydrolyzes the carboxy terminal
dipeptideHis-LeutoformtheoctapeptideAngII[8,12].This
conversion can also be accomplished by the chymotrypsin-
like serine protease, chymase [13] .A n g I Ii sc o n v e r t e dt ot h e
heptapeptide AngIII by glutamyl aminopeptidase A (APA:
EC 3.4.11.7, or A-like activity) that cleaves the Asp residue at
theN-terminal[14–17].MembranealanylaminopeptidaseN
(APN: EC 3.4.11.2) cleaves Arg at the N-terminal of AngIII
to form the hexapeptide angiotensin IV (AngIV). AngIV
can be further converted to Ang(3-7) by carboxypeptidase
P (Carb-P) and propyl oligopeptidase (PO) cleavage of the
Pro-Phe bond. Endopeptidases such as chymotrypsin are
capable of cleaving the Val, Tyr, and Ile residues, along with
dipeptidyl carboxypeptidase that cleaves the His-Pro bond,
reducing AngIV and Ang(3-7) to inactive peptide fragments
and aminoacid constituents [8, 18–22].
Some years ago the nomenclature committee of the
InternationalUnionofBiochemistry[23]indicatedthatAPA
was likely identical with APN. However, it has been shown
that APA cleaves the N-terminal Asp from AngII, but it also
cleaves Arg and Val [24] .T h es p e e do fA r ga n dV a lc l e a v a g e
was facilitated when a combination of APA and placental
leucine aminopeptidase (P-LAP) was used [25, 26].
AngII can also be converted to Ang(1-7) by Carb-P
cleavage of Phe [27], by the monopeptidase ACE2 [28, 29],
or by ACE cleavage of the dipeptide Phe-His from Ang(1-
9) [30]. Ang(1-7) is further converted to Ang(2-7) by APA
acting at the Asp-Arg bond [31]. AngII and AngIII are full
agonists at the AT1 and AT2 receptor subtypes (see [32, 33]
forreview).AngIVbindswithlowaﬃnityattheAT1 andAT2
receptorsubtypes,butwithhighaﬃnityandspeciﬁcityatthe
AT4 receptor subtype [34–39]. AngI is biologically inactive;
while its metabolites AngII and AngIII mediate pressor and
dipsogenic eﬀects via the AT1 and AT2 receptor subtypes
[32]. AngIV exerts a much reduced pressor response, also by
acting as an agonist at the AT1 receptor subtype [40–44].
A counter regulatory axis to the AngII-AngIII/AT1 recep-
tor system has recently been proposed consisting of ACE2,
andAng(1-7)actingattheMasreceptor.Thissystemappears
to act in opposition by promoting vasodilation, antiﬁbrosis,
antihypertrophicandantiproliferativeeﬀects(see[45,46]for
review) and is further discussed in the next section.
3. Characterization of the AT1,A T 2,
andMasReceptors
The AT1 receptor subtype is a G-protein-coupled receptor
with signaling via phospholipase-C and calcium. Thus, the
angiotensin ligand binds to the AT1 receptor and induces a
conformational change in the receptor protein that activates
G proteins, which in turn, mediate signal transduction. ThisInternational Journal of Hypertension 3
transductioninvolvesseveralplasmamembranemechanisms
including phospholipase-C, -A2, and -D-adenylate cyclase,
plus L-type and T-type voltage sensitive calcium channels
[32, 47, 48]. The AT1 receptor (now designated AT1A)i s
also coupled to intracellular signaling cascades that regulate
gene transcription and the expression of proteins that
mediate cellular proliferation and growth in many target
tissues. Expression cloning was used to isolate the cDNAs
encoding this receptor protein [49, 50], and it was found
to be a 7-transmembrane domain protein consisting of
359 aminoacids with a mass of approximately 41kDa [51].
Subsequently, a second AT1 subtype was discovered and
designated AT1B that was also cloned in the rat [52, 53],
mouse [54], and human [55]. This subtype is approximately
92–95% homologous with the aminoacid sequence of the
AT1A subtype [56, 57]. Of these two isoforms, the AT1A
subtype appears to be responsible for the classic functions
associated with the brain angiotensin system (see [58, 59]f o r
review).
TheAT2 receptorsubtypehasbeenclonedandsequenced
using a rat fetus expression library [60, 61], and also evi-
dences a 7-transmembrane domain characteristic of G-
protein-coupled receptors; however, it shows only about 32–
34% aminoacid sequence identity with the rat AT1 receptor.
The AT2 receptor protein includes a 363 aminoacid sequence
(40kDa) with 99% sequence agreement between rat and
mouse and 72% homology with human [32]. Even though
this AT2 receptor possesses structural features in common
with members of the 7-transmembrane family of receptors,
it displays few if any functional similarities with this group,
although it does appear to be G-protein-coupled [32, 60–
62]. While the AT1 receptor subtype is maximally sensitive
to AngII, it is also responsive to AngIII. The AT2 receptor
subtype appears to be maximally sensitive to AngIII, but
AngII also serves as a ligand at this receptor subtype.
TheMasreceptorwasdiscoveredin1986andwasinitially
categorized as a protooncogene because it transformed NIH
3T3 cells in a tumorigenicity assay (nude mice) using DNA
taken from a human epidermoid carcinoma cell line [63].
Subsequently, it was reported that overexpression of Mas
in cones of the retina caused cell death but no tumor
formation [64]. Further, transgenic mice overexpressing Mas
in the brain failed to reveal tumor formation [65]. Young
and colleagues [66] measured a high expression of the Mas
receptor in the hippocampus and neocortex of the rat brain.
The human Mas cDNA sequence indicated an open reading
frame coding for a 325 aminoacid protein [63] belonging
to the classiﬁcation of G-protein coupled receptors. Cellular
localization of Mas mRNA has been reported using in situ
hybridization with high levels detected in the rat and mouse
hippocampus and piriform cortex [67]. This receptor binds
Ang(1-7) with high speciﬁcity that could not be displaced
using AngII or AngIV [68]. While AngII, and to a lesser
extent AngIII, have been considered the active peptides
derived from angiotensinogen, convincing evidence exists
indicating that Ang(1-7) plays an important role in cardio-
vascular and pulmonary biology (see [69, 70] for review).
Ang(1-7), working through the Mas receptor, initiates many
biological responses that are opposite to those attributed
to AngII. These include vasodilatory, antihypertrophic,
antihyperplastic, and antiﬁbrotic action on the heart and
vasculature [71–73]. Unlike AngII, Ang(1-7) is generally
synthesized from AngII or Ang(1-9), and not AngI [74].
This synthesis is primarily carried out by ACE2 in the
heart, vasculature, lungs, and brain [75, 76]. The potential
clinically beneﬁcial eﬀects of augmenting the ACE2/Ang(1-
7)/Mas signaling system has spurred the development of
ACE2/Ang(1-7)/Mas system potentiating drugs including
Mas agonists and ACE2 activators [77].
The functions associated with the activation of each of
these receptors are presented in Table 1.
4. The PivotalRole of Aminopeptidases in
Blood PressureRegulation
As indicated above, APA hydrolyzes N-terminal acidic
aminoacids. It appears that glutamyl derivatives are more
eﬀectively hydrolyzed than aspartyl derivatives, thus this
enzyme has also been designated glutamyl aminopeptidase
(Glu-AP [22]). Aminopeptidase N acts on N-terminal neu-
tral aminoacids, and since alanine is most eﬃciently cleaved
by APN, this enzyme is also known as alanyl aminopeptidase
(Ala-AP). In addition, it has been referred to as aminopep-
tidase M (APM) because of its association with pig kidney
microsomal membrane fraction from which it was originally
puriﬁed. Aminopeptidase B (AP-B; EC 3.4.11.6) hydrolyzes
basic aminoacids at the N-terminal and is also known as
arginineaminopeptidase(Arg-AP).Cystinylaminopeptidase
(Cys-AP; EC 3.4.11.3) hydrolyzes the N-terminal cysteine
next to tyrosine of oxytocin and vasopressin. Thus, it is
frequently referred to as oxytocinase or vasopressinase. P-
LAP appears to be equivalent with Cys-AP; while insulin-
regulated aminopeptidase (IRAP) is the rat homologue of
Cys-AP [78, 79]. Since these enzymes are involved in metab-
olizing angiotensins, they have often been grouped under the
name “angiotensinases.’’
5. The Emergence of AngIII andAPA as Key
Factors in SustainingHypertension
It is now reasonably well established that a major reason
for high BP in the spontaneously hypertensive rat (SHR)
model is an overactive brain RAS, and the primary ligand
in this regard may be AngIII. Originally, it was reported
that intracerebroventricular (i.c.v.) infusion of AngII or
AngIII produced dose-dependent elevations in BP with the
magnitude of these elevations reasonably equivalent [80,
81]. Higher rates of neuronal ﬁring were shown with the
microiontophoresis of AngIII, as compared with AngII, in
both the subfornical organ (SFO) [82] and paraventricular
nucleus (PVN) [83, 84], two brain structures responsible for
mediating BP. Harding et al. [85], using a push-pull cannula
into the PVN, showed that 93% of the releasable angiotensin
coeluted with AngIII; while only 7% eluted with AngII. This
suggested that the conversion of AngII to AngIII is rapid and
a critical step in maintaining BP. It was next discovered that
SHRs were more sensitive to i.c.v.-infused angiotensins than
normotensive Wistar-Kyoto (WKY) and Sprague-Dawley4 International Journal of Hypertension
Table 1: Functions associated with ligand activation of the AT1,
AT2, and Mas receptors.
AT1 receptor subtype
Vasoconstriction
Aldosterone release
Vasopressin release
Cardiac hypertrophy
Fibrosis
Proliferation
Inﬂammation
Platelet aggregation
Oxidative stress
Endothelial disruption
AT2 receptor subtype
Vasodilation
Antiﬁbrotic
Antiproliferative
Antihypertrophic
Antithrombotic
Mas receptor
Vasodilation
Antiﬁbrotic
Antihypertrophic
Antithrombotic
Promotes endothelial function
rats. Further, these angiotensin-induced elevations in BP
remainedhighforlongerdurationsintheSHR.Pretreatment
with the APN inhibitor bestatin potentiated and prolonged
the pressor response to both AngII and AngIII. These results
suggested that inhibiting the conversion of AngIII to the
hexapeptide AngIV prolonged the half-life of AngIII, thus
providing a potential mechanism for the higher BP seen
in the SHR, that is, a delay in the conversion of AngII to
AngIII, and Ang III to AngIV. The extended half-life of brain
AngII and AngIII would be expected to prolong heightened
activation of the AT1 receptor subtype and thus maintain
an elevated BP. Pretreatment with bestatin potentiated and
prolongedthepressorresponsetobothAngIIandAngIII.We
interpretedtheseresultstosuggestthatinhibitingtheconver-
sion of AngIII to the hexapeptide AngIV prolonged the half-
life of AngIII, thus providing a plausible explanation for the
higher sustained blood pressure seen in the SHR. Next, we
demonstrated that the i.c.v. infusion of bestatin elevated BP
inbothSHRandWKYrats[86];whiletheinfusionofAla-AP
signiﬁcantlyreducedBPinSHRandWKYrats.Pretreatment
with the nonselective angiotensin receptor antagonist, [Sar1,
Thr8] AngII (sarthran, predecessor to Losartan) signiﬁcantly
diminished this Ala-AP-induced drop in BP in SHRs and
promoted recovery of BP and heart rate to baseline values
in members of both strains. Taken together, these results
pointed to an important role for brain AngIII interacting
with the AT1 receptor subtype.
Wesuspectedadisruptioninbrainaminopeptidaseactiv-
ity in the SHR [87, 88]. To test this hypothesis replacement
Glu-AP was i.c.v.-infused in order to promote the hydrolysis
of AngII to AngIII. Results indicated that BP was elevated in
both SHR and WKY rats [89]. In contrast, the i.c.v. infusion
of Ala-AP, which hydrolyzed AngIII, signiﬁcantly decreased
BP in WKY rats, but especially in SHRs. By the use of
metabolically resistant analogues of AngII ([D-Asp1] AngII)
and AngIII ([D-Arg1] AngIII), it was shown that the AngIII
analogue generated a much greater pressor response in the
SHR than the AngII analogue when i.c.v.-infused [90]. Taken
together, these results supported the notion that interfering
with the conversion of AngII to AngIII results in a signiﬁcant
reductioninBP[91],andbrainAngIIIisamuchmorepotent
pressor agent than AngII.
6. CurrentTreatment Strategies
In the periphery, the cardiovascular eﬀects due to excessive
formation of AngII bear a remarkable resemblance to those
observed in response to overactivation of the sympathetic
component of the autonomic nervous system and excess
norepinephrine. These include ventricular hypertrophy, vas-
oconstriction, and sodium retention. The synthesis cascade
involved in the formation of AngII oﬀers several opportu-
nities for clinical intervention, as does the interaction of
AngII and AngIII with the AT1 receptor subtype. These
potential points of intervention include treatment with renin
inhibitors, ACE inhibitors, APA inhibitors, aldosterone in-
hibitors, and angiotensin receptor blockers (ARBs).
6.1. Renin Inhibitors. As cardiovascular deﬁciency pro-
gresses, decreased renal perfusion occurs accompanied by
increased release of norepinephrine resulting in increased
juxtaglomerular renin release into the circulation. Renin is
an aspartic proteinase designed to cleave the Leu-Val bond
at the amino terminal of angiotensinogen, thus forming
the decapeptide AngI. This conversion is considered to be
the ﬁrst rate-limiting step of the RAS. First- and second-
generation renin inhibitors were peptidomimetics eﬀective
at lowering BP in hypertensive patients; however, these
inhibitors exhibited very poor oral bioavailability and were
subject to high production costs. Third-generation renin
inhibitors are nonpeptides, such as Aliskiren, and appear to
bemoretherapeuticallypromisinginthattheyevidencegood
duration of action and bioavailability [92].
6.2. ACE Inhibitors. The next potential point of intervention
intheangiotensinsyntheticcascadeistheconversionofAngI
to AngII, where ACE inhibitors have utility. ACE hydrolyzes
the carboxy terminal dipeptide His-Leu to form AngII
[8]. ACE inhibitors have become a primary therapeutic
treatment for hypertension and systolic heart failure. The
myocardium of patients with failing hearts shows increased
levels of ACE mRNA, ACE protein, and ACE activity [93].
The notion that hemodynamic load determines the level of
RAS expression in the heart is supported by the observation
that ACE increases as the severity of heart failure increases.
In agreement, left ventricle ACE and AngII levels change
with diastolic ventricular wall stress [94]. A disadvantage
of ACE inhibitors concerns their ability to prevent theInternational Journal of Hypertension 5
breakdown of bradykinin to inactive peptide fragments.
This can result in an accumulation of bradykinin that
contributes to angioedema and cough. In some patients,
these side eﬀects can be suﬃciently troublesome to result in
discontinuation of the medication. Even so ACE inhibitors
appear to provide long-term positive eﬀects in many patients
with heart failure. Paradoxically, these beneﬁcial eﬀects
may be due to the buildup of bradykinin which facilitates
reduced norepinephrine synthesis and release, vasodilation,
and general antiproliferative eﬀects [95].
6.3. Aldosterone Receptor Antagonists. Early on, it was as-
sumed that ACE inhibitors would adequately limit the syn-
thesis of aldosterone given AngII’s ability to facilitate aldos-
terone production. However, ACE inhibition causes a tran-
sient depression in circulating aldosterone levels followed by
recovery after only a few days. This turns out to be a particu-
larlyimportantlimitationofACEinhibitioninthetreatment
of heart failure [96]. Elevations in circulating aldosterone
have long been known to increase sodium reabsorption
and potassium excretion, but increased aldosterone elevates
cytokines, promotes vascular inﬂammation and endothelial
malformation,and alsomyocardial ﬁbrosis andhypertrophy.
Animal model work has demonstrated a signiﬁcant role
for elevated aldosterone levels contributing to myocardial
ﬁbrosis [97] and left ventricular remodeling [98]. McKelvie
and colleagues [99] showed that standard therapy (ACE
inhibitor, ARBs, and β-adrenergic receptor antagonist) failed
to reduce circulating aldosterone levels in patients with
heart failure due to left ventricular systolic dysfunction. Pitt
et al. [100] treated hypertensive patients, complicated by
left ventricular hypertrophy, with the selective aldosterone
receptor antagonist Eplerenone, the ACE inhibitor Enalapril,
or a combination of the two. Eplerenone (mean = −14.5g)
decreasedleftventricularmasssimilartoEnalapril(−19.7g),
but combined treatment (−27.2 g) was more eﬀective. These
results suggest that an ACE inhibitor alone is not suﬃcient to
maximize left ventricular mass reduction.
6.4. Angiotensin Receptor Blockers. Given the importance of
the AT1 receptor subtype’s role in contributing to the car-
diovascular continuum, it seems reasonable that speciﬁc
angiotensin receptor blockers could signiﬁcantly reduce
cardiovascular risk factors. Initial studies in canine models
of left ventricular diastolic hypertrophy revealed beneﬁcial
eﬀects due to ARB treatment [101]. The Losartan Interven-
tion for Endpoint Reduction in Hypertension (LIFE) study
found regression of left ventricular hypertrophy following
long-term treatment with Losartan or Atenolol [102]. A
s t u d yb yD ´ ıez and colleagues [103]t r e a t e dh y p e r t e n s i v e
patients with severe or nonsevere myocardial ﬁbrosis with
Losartan for 12 months. These patients demonstrated a clear
improvementinleftventricularchamberstiﬀnessascorrelat-
ed with a reduction in collagen fraction volume, particularly
in the severe ﬁbrosis patients.
The Candesartan in Heart Failure Assessment of Reduc-
tion in Mortality and Morbidity (CHARM) study evalu-
ated the contribution of ARBs in combination with ACE
inhibitors, β-adrenergic antagonists, and aldosterone recep-
tor antagonists in a large group of heart failure patients
possessingleftventricularejectionfractiongreaterthan40%.
There was a trend toward fewer cardiovascular problems
with Candesartan treatment than placebo [104]. However,
there was an accompanying hyperkalemia and/or elevated
creatinine levels in these patients.
7. Novel Treatment Strategies
Three novel approaches to the treatment of hypertension
have focused on inhibiting the enzymes involved in the for-
mation of AngII and AngIII, or incrementing the enzymatic
pathway such that these angiotensins are rapidly degraded.
7.1. Reduction in Brain AngIII Formation via Inhibition of
APA. TheLlorens-Cortesresearchgrouphasextendedinitial
work completed with amastatin and bestatin by designing
inhibitors with improved speciﬁcity. Reaux et al. [105]
synthesizedtwoinhibitors:onespeciﬁcforAPAreferredtoas
EC33 and a second speciﬁc to APN called PC18 (m.w.=120–
130 kDa for the monomer). Intracerebroventricular pre-
treatment with EC33 blocked the elevation in BP typically
induced by the i.c.v. infusion of AngII in anesthetized SHRs.
These results suggested that the AngII pressor response
depended upon conversion of AngII to AngIII. Further,
the i.c.v. infusion of EC33 caused a large dose-dependent
decline in BP in conscious SHRs, as well as conscious
DOCA-salt treated rats (a salt/volume-dependent and renin-
independent model of hypertension) (Table 2 [106, 107]).
This eﬀect could not be induced by intravenous infusion of
EC33,suggestingthatEC33didnotpenetratetheBBBand/or
was not peripherally eﬀective. These results were interpreted
tosuggestthatin addition toreducing conversionofAngIIto
AngIII, EC33 also encouraged degradation of accumulating
endogenous AngII by peptidases including endopeptidases
and carboxypeptidases, for example, ACE2 [108–110]. This
wouldbeexpectedtoresultintheformationofsmallerAngII
fragments possessing very low, or no, AT1 receptor aﬃnity.
The conclusion that AngIII is the active ligand acting
at the AT1 receptor subtype was further supported in that
i.c.v.-infused PC18 in SHRs signiﬁcantly increased BP [105].
This PC18-induced pressor response could be prevented
by pretreatment with the speciﬁc AT1 receptor antagonist
Losartan, but not by the speciﬁc AT2 receptor antagonist
PD123319. Thus, these results suggest that the inhibition of
APN results in the accumulation of endogenous AngIII with
increased binding at the AT1 receptor subtype causing an
increaseinBP.Ourlaboratoryconﬁrmedthesebasicﬁndings
using metabolic-resistant analogues: D-Asp1-AngII and D-
Arg1-AngIII i.c.v.-infused in conscious normotensive rats in
the presence or absence of EC33 or PC18 (Table 2 [91]). And
ﬁnally the i.c.v. infusion of APA signiﬁcantly increased blood
pressure in conscious SHRs; while the i.c.v. infusion of APN
decreased BP [88]. This hypertensive eﬀect was attributed to
increased endogenous levels of AngIII, and the hypotensive
eﬀect to increased AngIII degradation. Along these lines,
Song and colleagues [116] reported that i.c.v. infusion of
an antiserum against APA activity signiﬁcantly reduced6 International Journal of Hypertension
Table 2: Summary of investigations supporting a role for EC33 and PC18 (EC27) in blocking the release of vasopressin and controlling
hypertension in animal models.
Preparation Finding Reference
Synthesis of EC33 Designed by Chauvel as a speciﬁc inhibitor of APA [111]
Synthesized by Reaux and colleagues
i.c.v. infusion-mice
EC33 increased the half-life of [3H]AngII by 2.6 fold and blocked the formation of
[3H]AngIII [108]
PC18 and EC27 increased the half-life of [3H]AngIII by 3.9 and 2.3 fold, respectively [108, 111]
EC33 reduced AngII-induced vasopressin release in a dose-response-dependent fashion [111]
Injection of PC18 and EC27 increased vasopressin release [111]
Normotensive rats Recorded from vasopressinergic neurons in the SON
(urethane-anesth.)
i.c.v. infusion of AngII and AngIII signiﬁcantly increased ﬁring rate. i.c.v. infusion of
EC33 abruptly stopped ﬁring rate for 4–6min. i.c.v. infusion of AngII followed by EC33
prevented the increase in ﬁring rate to AngII
[112]
i.c.v. infusion-SHRs EC33 blocked AngII-induced pressor responses [105, 113]
i.c.v. infusion-
normotensive
rats
EC33 blocked the pressor response induced by AngII and D-Asp1AngII but had no eﬀect
on the pressor responses induced by AngIII or D-Arg1AngIII. PC18 extended the
duration of the D-Asp1AngII-induced pressor response 2.5 fold, and the duration of the
D-Arg1 AngIII-induced pressor response by 10 to 15 fold. Pretreatment with Losartan
blocked these pressor responses, indicating AT1 receptor involvement
[91]
Synthesis of RB150 Designed by Fournie-Zaluski [107]
DOCA-salt rats Intravenous administration of RB150 signiﬁcantly reduced BP for 24 hours [107]
Oral administration of RB150 signiﬁcantly reduced BP for 7 hours [114, 115]
AngII-induced BP increases by ∼60%. Taken together, these
ﬁndings illustrate the importance of AngII conversion to
AngIII in the brain but not in the periphery, regarding the
mediation of BP. Thus, endogenous brain AngIII appears to
exert a maintained tonic inﬂuence on centrally controlled
BP in conscious normotensive and hypertensive animals.
It is noteworthy that the inhibition of APA reduced BP to
normotensive levels in hypertensive rat models.
These ﬁndings have resulted in the development of a
selective orally active APA inhibitor (RB150) capable of
crossing the blood-brain barrier and functioning as a antihy-
pertensive drug (Table 2 [107]). RB150 is a pro-drug of EC33
formed from two molecules of EC33 linked by a disulﬁde
bridge.Thepresenceofthethiolgroupinthedisulﬁdebridge
prevents interaction with the zinc atom at the APA site.
This bridge appears to permit BBB penetration, and once
in the brain the disulﬁde bridge is removed by reductases,
it yields two active EC33 molecules [117]. RB150 has been
shown to function as an antihypertensive drug when given
intravenously [107]o rb yg a v a g e[ 114].
7.2. Facilitation of Angiotensin Degradation. There is con-
siderable discrepancy in ﬁndings regarding the importance
of AngIII as a mediator of peripheral BP. For example,
Ahmad and Ward [118], using amastatin and bestatin,
failed to conﬁrm an important role of APA in the systemic
RAS. In contrast to the ﬁnding that i.c.v.-infused EC33-
induced a nearly complete inhibition of APA in the rat
brain [108], intravenous infusion of EC33 resulted in only
limitedblockadeofplasmaAngIIconversiontoAngIII[117].
There are several possible explanations for these diﬀerences
comparing the brain and the periphery: (1) AngIII could
be more rapidly metabolized than AngII in the periphery.
However, our laboratory has determined the half-life of
AngIII in the vasculature of normotensive rats to be 16.3
seconds; while the half-life of AngII was 12.5 sec [119]; (2)
the major enzyme responsible for converting AngII to AngIII
intheperipheryisnotAPA.Thisisunlikelygiventhenumber
of studies pointing to an important role for APA in this
regard (see [16–18, 20, 22, 105, 120–123] for review); (3)
related to the above, alternative enzymatic pathways could be
present in the peripheral circulation, for example, ACE2 may
play an important role [29, 69, 124]. Clearly, there are many
more enzymes involved in the metabolism of angiotensin
than APA and APN [10].
As described above, the removal of the C-terminal His-
Leu from AngI by ACE to form AngII, the conversion of
AngII to AngIII due to the removal of Asp by APA, and
the subsequent conversion of AngIII to AngIV with the
removal of Arg by APN, are critical steps in determining
the availability and survival rates of circulating AngII and
AngIII. The hydrolysis of AngII to AngIII by APA could be
the rate-limiting step in determining the level of activity
of AT1 receptor activation in the periphery (see [25, 125]
for review). In agreement with the importance of APA,
recombinant human APA [126] has been shown to have
value as an antihypertensive treatment in SHRs [127]. The
eﬀective dose of APA was approximately one-tenth that of
the ARB Candesartan. This approach was spawned from the
original observation that the SHR resembles human essentialInternational Journal of Hypertension 7
hypertension in that ACE inhibition, or ARB treatment,
normalized BP [128, 129]. These results emphasize the
importance of the RAS to the hypertension seen in this
animal model. It was next conﬁrmed that intravenous
infusion of APA plus APN (puriﬁed from human placenta)
lowered AngII-induced hypertension in normotensive rats
[130];whileAPAnormalizedBPinSHRs[131].Theseresults
suggested that elevated APA could be eﬀective in controlling
high BP; while impairment of APA activity contributed to
the development of hypertension. This observation supports
theﬁnding thatSHRshaveimpairedaminopeptidase activity
[132]; while renal APA activity in the SHR was found to be
lower than in age-matched WKY rats [133].
The use of puriﬁed and recombinant APA is certainly
worth considering for the treatment of hypertensive emer-
gencies such as acute hypertensive crisis, preeclampsia, acute
heart failure, and hypertensive encephalopathy [134, 135].
However, the notion that AngIII is the primary ligand
acting at the AT1 receptor subtype in the brain’s control of
BP points to the importance of inhibiting APA in hyper-
tension (Llorens-Cortes hypothesis). On the other hand, the
proposal that AngII is the primary ligand acting at the AT1
receptor subtype suggests that elevations in APA should be
eﬃcacious in controlling hypertension (Mizutani hypothe-
sis). Additional research eﬀort will be necessary to resolve
this important issue.
7.3. APN Inhibitors. Finally, there is growing interest in the
development of APN inhibitors [136].Thehuman APNgene
consists of 20 exons and maps to chromosome 15q25-26
[137]. With the use of adipocyte-derived APN, 33 polymor-
phisms have been identiﬁed [138]. Two of eight missense
polymorphisms have been associated with arterial blood
pressure, and one (Lys528Arg) has been linked to essential
hypertension [138, 139]. This Lys528rg polymorphism has
been reported to inhibit APN enzymatic activity [126].
Increased urinary APN levels have been measured in renal
transplant rejection patients [140] and renal cell carcinoma
patients [141]. A recent study by Padia and colleagues [142]
noted a defect in sodium excretion in young SHRs prior
to the onset of hypertension. In this regard, young WKY
rats evidenced twice the excretion rate of sodium attributed
to reduced renal proximal tubule sodium reabsorption. The
renal interstitial infusion of PC18 corrected this natriuresis
by incrementing sodium excretion. Thus, the inhibition
of AngIII metabolism by inhibiting APN corrected this
proximal tubule defect in sodium excretion in SHRs. The
renal interstitial infusion of AngIII produced a natriuresis in
normotensive rats that was dependent on the AT2 receptor
subtype [143]. The authors argue that conversion of AngII
to AngIII is necessary for this natriuresis, and AT1 receptor
blockade with Candesartan failed to impact these AngIII-
induced eﬀects. The potential use of APN inhibitors for
inﬂammatory disease and malignancies is being considered
[144]; however, the testing of APN inhibitors to treat hyper-
tensivepatientsisjustnowbeginning.Itshouldbenotedthat
the use of APN inhibitors to control hypertensive disorders
is controversial, and this area is in need of additional careful
research attention.
8. Conclusion
Research interest in understanding the role of the RAS in
the control of BP has been ongoing for over 100 years,
and yet new discoveries continue to be made. Hypertension
is present in approximately 16% of the adult population
of the world, and 95% are categorized as essential hyper-
tension treated with the major classes of antihypertensives
including diuretics, ACE inhibitors, ARBs, β-blockers, and
calcium channel blockers [145, 146]. Despite the availaiblity
of over 75 antihypertensive drugs, approximately 65% of
hypertensivepatientsarenotabletocontroltheirelevatedBP
[147]. And the incidence of “resistant hypertension” despite
the combination of three or more drugs is around 15% of
the hypertensive population [147]. Thus, we are in need
for novel approaches to better treat these patients. It now
appears that the importance of brain AngIII has been signif-
icantly underestimated in that the conversion of brain AngII
to AngIII by APA has a major inﬂuence upon the regulation
of BP and release of vasopressin. In this regard, AngIII may
exert a persistent tonic inﬂuence upon BP. It is surprising
that a selective APA inhibitor such as EC33 decreases BP
when given centrally but not peripherally. It must be added
that available results concerning RB150 are consistent in
this regard. With respect to the potential use of an orally
active APA inhibitor, a number of important issues remain
including but not limited to: (1) the relative importance
of AngIII and APA to blood pressure control comparing
the brain and peripheral systems; (2) the inﬂuence of other
peptidasesupontheformationofangiotensinligands;(3)the
signiﬁcanceoftheAT2 receptorsubtype,andAng(1-7)acting
at the Mas receptor, in the control and treatment of essential
hypertension.
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